:::::::::: 글로벌번역통역센터 ::::::::::
 
 



 
 
> 고객지원센터 > News & Notice
ADMIN 2020. 09. 28.  
LIST  MODIFY  DELETE  WRITE  REPLY 
   제목: Celltrion fires opening salvo against JPMorgan


Celltrion fires opening salvo against JPMorgan


September 11,2020

By Park Jae-hyuk

Celltrion, Korea's leading pharmaceutical company, hinted at taking legal action against top-tier U.S. investment bank JPMorgan, by claiming the bank's recent investment reports on the firm defamed its chairman Seo Jung-jin and the company.

Celltrion held an emergency briefing for securities firm analysts here, Thursday, after the company officially raised questions about the credibility of the recent JPMorgan investment reports. The Korea Times reached out JPMorgan for any comments on Celltrion's claim, but received no response.

The possibility came after JPMorgan & Chase abruptly accentuated its negative outlook for the Korean pharmaceutical firm.

In the report published by JPMorgan analyst Cho Ji-hyun, Wednesday, the investment bank suggested a reduction of investments in Celltrion shares, setting its target price at 190,000 won ($160), about 60 percent of the previous session's closing price of 318,000 won.

As for Celltrion Healthcare share, JPMorgan set its target price at 70,000 won, about 70 percent of the previous session's closing price of 103,100 won.

JPMorgan said Celltrion's annual earnings growth will peak at 54 percent in 2020 and fall to 21 percent in 2021, warning investors against being too optimistic about its development of potential COVID-19 treatments.

As the stock prices of Celltrion and Celltrion Healthcare respectively dropped 6.13 percent and 4.36 percent after the issuance of the report, the Korean pharmaceutical company claimed JPMorgan seemingly published an "unreasonable report" to undervalue Celltrion, compared to its rival.

In the same report, JPMorgan raised the target price of an ordinary share of Samsung Biologics to 840,000 won from 416,000 won. Samsung Biologics closed at 774,000 won a day before the publication of the report.

"Based on its own estimation of the 2021 earnings, JPMorgan calculated our rival's price to earnings ratio (PER) next year to be 158 times, while Celltrion's to be 76 times and Celltrion Healthcare's 57 times," Celltrion CEO Kee Woo-sung said in a statement. "However, it suggested 'underweight' for Celltrion and Celltrion Healthcare, while proposing 'neutral' for our rival."

Local investors suspected the U.S. investment bank was intentionally trying to drag down its stock price. They said behind its negative outlook was its sales arm, which had conducted a massive amount of short selling of Celltrion shares until the nation's financial authorities imposed a temporary ban on the investment scheme, following the spread of COVID-19 in March. Short selling is an investment move betting on a drop in a stock price.

In contrast to JPMorgan, local brokerages have had optimistic outlooks for Celltrion, saying its growth rate shows there is enough room for its stock price to go up further. According to online financial data tracker FnGuide, Korean securities firms set the target price of Celltrion shares at 371,769 won on average.

Over the past few years, Celltrion has suffered from negative reports issued by foreign investment banks, including Goldman Sachs, Deutsche Bank and Morgan Stanley.

Their reports have been considered to be aimed at short selling of the Korean company shares, although they have emphasized that their "Chinese Wall" strictly bars their research and sales arms from exchanging information with each other.

According to industry officials, JPMorgan accounted for 8.2 percent of short selling of Celltrion shares during the first three months of this year.

A high-ranking executive at a local securities firm wishing to remain anonymous raised doubts whether the Chinese Wall in investment banking are really intact, saying foreign firms here are not under as strict supervision by the financial authorities as domestic firms are.

Excerpts articles from The Korea Times
LIST  MODIFY  DELETE  WRITE  REPLY 





전체글 목록 2020. 09. 28.  전체글: 762  방문수: 2396248
 공지  정규직,계약직,프리랜서직 모집 
762   Virus's unseen hot zone: The American farm
761   Climate change, infectious disease seen as major threats: survey
760   Singapore and Hong Kong Are Top Asia Destinations for Suspect Funds
759   New virus cases under 100 for 2nd day; untraceable cases still hurdle in virus fight
758   Why foreign firms are leaving Korea
757   Coronavirus cases top 30 million worldwide
756   Esper says 'Quad' will be more effective than bilateral alliance
755   Why does Kakao want an insurer?
754   Oracle Beats Microsoft in Deal for TikTok뭩 U.S. Operations
753   Celltrion fires opening salvo against JPMorgan
752   JPMorgan Finds Some Workers Improperly Pocketed Relief Funds
751   GM to make electric vehicle, supply batteries for Nikola
750   Xi''s Post-Virus Economic Strategy for China Looks Inward
749   NATO demands Moscow reveal Novichok programme
748   US preparing for Nov. 1 rollout of first coronavirus vaccine: report
747   Steven Cohen's Redemption Tour
746   How a Powerful Nissan Insider Tore Apart Carlos Ghosn’s Legacy
745   US dollar, gold on divergent path amid pandemic
744   Ant's IPO Is Set to Make Group of Elite Insiders Very Rich
743   Thailand Seeks Local Production Rights to Oxford뭩 Covid Vaccine
742   Japan's Economy Contracts 7.8 Percent, Worst Decline on Record
741   Hong Kong newspaper raided, tycoon detained under new law
740   Uber's Revenue Craters, as Deliveries Surge in Pandemic
739   Businesses Thought They Were Covered for the Pandemic. Insurers Say No.
738   SK, Samsung push into financial software market
737   U.S. Economy,s Rebound Looks Shakier After Worst Quarter Yet
736   Amazon, Apple, Facebook and Google Prepare for Their 멊ig Tobacco Moment
735   China will start giving visas to Koreans soon
734   Bubble Warnings Get Louder With Nasdaq Erasing Huge Monday Rally
733   BTS charts three on Billboard 200
RELOAD VIEW DEL WRITE
1 [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] 26